Kos Biotechnology Partners, a global investment firm focusing on life sciences, has completed a funding round for Epikast, a biopharmaceutical company headquartered in New York but with significant operations in Athens, Greece. This marks Kos’s first investment from their inaugural fund, which aims to support a wide range of investment stages in impactful life sciences platforms, from seed funding to scaling operations. Following this funding, the CEO and co-founder of Kos, Alexandros Tzoukias, will join Epikast's Board of Directors.

The capital injection is designed to enhance Epikast's proprietary technology platform and scale its specialized service teams. Epikast effectively bridges high-level medical expertise with cost-efficient operations, utilizing its operational hub in Greece to serve global biopharmaceutical clients. This investment not only reinforces the collaborative ecosystem in the Greek life sciences sector but also highlights the potential for international partnerships between Greek companies and foreign investors.

Overall, this funding round may signal a growing interest in the Greek biopharmaceutical landscape, promoting further investments and innovation in the sector. It reflects the strategic efforts by Kos Biotechnology Partners to identify and support promising life sciences ventures that can address global healthcare challenges, leveraging the strengths of their operational areas and networks to foster the growth of emerging companies like Epikast.